Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06950814

Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma

In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Sarcomatoid Carcinoma Adjuvant Therapy Carcinoma Digestive System Diseases Digestive System Neoplasms Liver Cancer Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

West China Hospital

Chengdu, Sichuan, 610041, China

Location status: Recruiting

Location contact

Jiwei Huang Huang Professor

CONTACT

[email protected]

+86 18980606725

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients who underwent liver resection
  • patients' postoperative paraffin pathology and immunohistochemistry results were reviewed to identify those diagnosed with PHSC

Exclusion criteria

  • patients who received other anti-tumor treatments before surgery, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), radiation therapy (RT), and systemic therapy;
  • patients diagnosed with other specific types of sarcomas;
  • patients with concurrent other malignancies during the course of PHSC;
  • patients who were lost to follow-up or lacked essential clinical data.

Treatment and study plan

postoperative adjuvant therapy

Procedure

Given the rarity and high aggressiveness of PHSC, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines.

Primary outcomes

  1. Disease-free survival

    Time frame: From December 2018 to May 2023

    Disease-free survival (DFS) was defined as the time from liver resection to disease recurrence or death from any cause.

Secondary outcomes

  1. Overall survival

    Time frame: From December 2018 to May 2023

    Overall survival (OS) was defined as the interval from liver resection to death or the last follow-up.

Study contacts

Contact information is provided by the study sponsor or research team.

Jiwei Huang Professor

CONTACT

[email protected]

+86 18980606725

Sponsors and collaborators

Lead sponsor

West China Hospital

Other

Registry information

Official study title

Prognostic Impact of Adjuvant Therapy Following Surgical Resection in Primary Hepatic Sarcomatoid Carcinoma: A Retrospective Cohort Study

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Apr 30, 2025
Registry last updated
Apr 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.